

Konstantynów Łódzki, February 9, 2023

Press Release

Mabion with tenth order under Novavax partnership

- > On February 9, 2023, Mabion signed a further extension to the scope of services of the Manufacturing Agreement with Novavax, in the form of Statement of Work #10 ("SOW#10").
- > The scope of SOW#10 includes logistics services, including transportation and storage of materials, active substances of vaccines and finished products
- > Mabion, a fully integrated biopharmaceutical company, has GMP (Good Manufacturing Practice) certification for the full range of manufacturing activities - production, quality control, logistics, so all SOW#10 services will be performed in this environment
- > The remuneration payable to Mabion for the implementation of SOW#10 will depend on the volume of transportation services and products ordered by Novavax for storage, including the storage period. The estimated value of orders in the first year will be more than PLN 1 million
- > In the last 12 months, Mabion has signed a total of 6 additional orders under individual SOWs, and since the start of its cooperation with Novavax in October 2021, the number of concluded SOWs has reached 10
- > Regularly acquired SOW orders are the result of systematic and effective monetization of the competencies Mabion has built over the years
- > Mabion is in the process of technology transfer regarding the manufacture of an active substance based on the Omicron variant, confirming its ability to act quickly and effectively in bringing new products into production

*"The SOW#10 we signed is a renewed expansion of not only the cooperation with Novavax itself, but another confirmation of the Company's huge potential in the CDMO area, to which we are now adding a component in the form of transportation and storage in a GMP environment. Operationally, we are prepared to provide this kind of service to more entities, and the execution of the order will be a very good reference for us. I think the signing of SOW#10 shows how widely Mabion can commercially exploit its high degree of integration," - says **Slawomir Jaros, Mabion S.A. Board Member for Operations and Scientific Affairs.** "In parallel with the execution of orders under numerous SOWs, we are working intensively on the process of transferring the vaccine antigen manufacturing technology for the Omicron variant. We are carrying out this work in accordance with expectations and the schedule agreed with Novavax," **Slawomir Jaros added.***

The scope of activities implemented by Mabion under SOW#10 includes logistics services, including transportation and storage of materials, active substances of vaccines of finished products. These services will be provided in a GMP environment and in accordance with the transportation and storage conditions agreed upon by Mabion and Novavax. Remuneration will depend on the number of orders received by Mabion for both transportation and storage services, including the established storage period for products. The estimated value of orders in the first year will be more than PLN 1 million.

The regularly expanded scope of cooperation with Novavax under signed SOW orders is part of Mabion's strategic direction in the CDMO area. The company has a team of specialists and a state-of-the-art facility that is perfectly suited to respond to market needs. The complete range of services offered by Mabion, from the development and structural and functional characterization of the product and process, through manufacturing at scale

commercial fully GMP-compliant, makes the Company a natural partner for companies that do not have the in-house expertise and assets necessary to carry out product development and production on a commercial scale.

"The development of our CDMO business is crucial for us, especially at the current moment, when we are in a series of discussions with potential new customers to diversify the business. From their perspective, the key factors are the broad competence, which we confirm through our regularly expanded cooperation with Novavax, as well as the comprehensiveness of our offer, which is why we are constantly expanding the range of services we offer and adding other important components. Currently, we already have 10 signed orders within individual SOWs and, importantly for us, they appear systematically, based, among other things, on satisfaction with the level of service within previous orders,"
comments Adam Pietruszkiewicz, Mabion S.A. Board Member for Sales.

Until 2021, the Company focused on developing its portfolio of proprietary biological products. The agreement with the U.S. entity Novavax, concluded in October 2021, saw Mabion successfully begin to commercialize the competencies it had built and initiated its transformation into a fully integrated GLP and GMP certified biopharmaceutical company with CDMO services in the form of analytics and contract manufacturing. The successful implementation of the \$372 million agreement with Novavax was extended until the end of 2026 as a result of annexes concluded in September 2022, with guaranteed revenue levels until at least the second quarter of 2024. In addition, the annexes expanded Mabion's remuneration terms with another component - the Company under the annexes will receive remuneration for manufactured product batches or remuneration for readiness to manufacture product (capacity reservation). The annexes also expanded cooperation with plans to transfer technology and manufacture the active substance for the Omicron version of the vaccine, this work is already underway.

Contact for media and individual investors

Michał Wierzchowski

+48 531 613 067

+48 22 440 14 40

michal.wierzchowski@ccgroup.pl

Mardoniusz Maćkowiak

+48 605 959 539

+48 22 440 14 40

mardoniusz.mackowiak@ccgroup.pl

Contact for institutional investors and analysts

Piotr Owdziej

+48 697 612 913

+48 22 440 14 40

piotr.owdziej@ccgroup.pl

Katarzyna Mucha

+48 697 613 712

+48 22 440 14 40

katarzyna.mucha@ccgroup.pl

Information about Mabion S.A.

Mabion S.A. (WSE: MAB) is a fully integrated Polish biopharmaceutical company founded in 2007, whose main focus is the design and development of the latest generation of drugs based on recombinant protein technology (e.g. monoclonal antibodies). Mabion's competencies include the drug design phase, as well as the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances "Drug Substance" and Finished Products "Drug Product"), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The company's most advanced project is MabionCD20, a biosimilar drug to MabThera (rituximab) with therapeutic indications for non-Hodgkin's lymphoma, leukemia and rheumatoid arthritis (RA). In addition, since signing a contract with Novavax in October 2021 for commercial manufacturing of the vaccine for COVID-19, Mabion has been developing and expanding its existing platform to include CDMO activities, i.e. contract development services, GMP manufacturing and GMP/GLP analytical services across the full range of the above capabilities. Mabion is a public company, listed on the Warsaw Stock Exchange.

For more information about the Company, visit www.mabion.eu